Journal
DRUG DISCOVERY TODAY
Volume 23, Issue 12, Pages 1983-1989Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2018.08.001
Keywords
-
Categories
Funding
- NIH/NIA [R37AG037319, R01AG044793, R01AG053041, R21AG058985]
- NIH/NINDS [R01NS089116]
Ask authors/readers for more resources
The mitochondrial permeability transition pore (mPTP) has been considered a key contributor to cell death, inducing the process in several major neurodegenerative diseases. To date, the molecular nature of the mPTP remains confounding but its significance is universally acknowledged. Several targets have been screened and inhibition of mPTP has emerged as an attractive field for researchers. Nowadays, in silico-directed studies help to explore new small molecules targeting the mPTP to improve their drug-like properties and bioactivity. Here, we briefly summarize the role of mPTP in neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson disease (PD), and Huntington's disease (HD), and discusses current and future potential therapeutic targets.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available